Search Result

Results for "

RPMI

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Apoptosis (7) Autophagy (4) Biochemical Assay Reagents (1) c-Myc (2) Cannabinoid Receptor (1) Caspase (4) CD38 (1) DNA/RNA Synthesis (1) Drug Metabolite (2) Elastase (1) Fungal (1) HDAC (3) Histone Demethylase (1) Histone Methyltransferase (1) IKK (1) Integrin (1) IRE1 (4) Isotope-Labeled Compounds (1) Mitochondrial Metabolism (1) Molecular Glues (1) Monoamine Oxidase (1) NF-κB (1) p38 MAPK (1) p62 (1) p97 (1) Parasite (2) PROTACs (1) Proteasome (5) Reactive Oxygen Species (ROS) (1) Reference Standards (2)
By Research Areas:	Cancer (24) Cardiovascular Disease (1) Endocrinology (1) Infection (4) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (1)

By Targets:

Antibiotic (1)

Apoptosis (7)

Autophagy (4)

Biochemical Assay Reagents (1)

c-Myc (2)

Cannabinoid Receptor (1)

Caspase (4)

CD38 (1)

DNA/RNA Synthesis (1)

Drug Metabolite (2)

Elastase (1)

Fungal (1)

HDAC (3)

Histone Demethylase (1)

Histone Methyltransferase (1)

IKK (1)

Integrin (1)

IRE1 (4)

Isotope-Labeled Compounds (1)

Mitochondrial Metabolism (1)

Molecular Glues (1)

Monoamine Oxidase (1)

NF-κB (1)

p38 MAPK (1)

p62 (1)

p97 (1)

Parasite (2)

PROTACs (1)

Proteasome (5)

Reactive Oxygen Species (ROS) (1)

Reference Standards (2)

By Research Areas:

Cancer (24)

Cardiovascular Disease (1)

Endocrinology (1)

Infection (4)

Inflammation/Immunology (3)

Metabolic Disease (1)

Neurological Disease (1)

Inhibitors & Agonists

Biochemical Assay Reagents

MCE Kits

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10455

Carfilzomib Maximum Cited Publications 65 Publications Verification PR-171	Proteasome Autophagy Apoptosis	Cancer
Carfilzomib (PR-171) is an irreversible proteasome inhibitor with an IC₅₀ of 5 nM in ANBL-6 and RPMI 8226 cells.

HY-N0176

Dihydroartemisinin 40+ Cited Publications Dihydroqinghaosu; β-Dihydroartemisinin; Artenimol	Parasite NF-κB Autophagy Reactive Oxygen Species (ROS) Drug Metabolite	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Dihydroartemisinin is an orally active metabolite of rtemisinin (HY-B0094) and antimalarial agent. Dihydroartemisinin induces Autophagy by inhibiting NF-κB activation. Dihydroartemisinin promotes ROS accumulation. Dihydroartemisinin exhibits anticancer activity in esophageal cancer cells. Dihydroartemisinin shows schistosomicidal activity against juvenile and adult worms of Schistosoma japonicum, reduces worm burden, and displays antiparasitic activity. Dihydroartemisinin can be used in research related to multiple myeloma, promyelocytic leukemia, esophageal cancer, and Schistosoma japonicum infection .

HY-150287

Insulin-Transferrin-Selenium, 100X 5+ Cited Publications ITS-G	Biochemical Assay Reagents	Endocrinology
Insulin-Transferrin-Selenium, 100X (ITS-G) is a mixture of Insulin, transferrin, and sodium selenite that is a general supplement designed for use in classic media such as DMEM, RPMI-1640, and nutrient media such as Ham's F-12, DMEM/F-12. Insulin-Transferrin-Selenium is added to basal medium to reduce the amount of fetal calf serum required to culture cells .

HY-104040

MKC8866 15+ Cited Publications Orin1001	IRE1	Cancer
MKC8866, a salicylaldehyde analog, is a potent, selective IRE1 RNase inhibitor with an IC₅₀ of 0.29 μM in human vitro. MKC8866 strongly inhibits Dithiothreitol-induced X-box-binding protein 1-spliced (XBP1s) expression with an EC₅₀ of 0.52 μM and unstresses RPMI 8226 cells with an IC₅₀ of 0.14 μM . MKC8866 inhibits IRE1 RNase in breast cancer cells leading to the decreased production of pro-tumorigenic factors and it can inhibits prostate cancer (PCa) tumor growth .

HY-P9984

Etrolizumab 2 Publications Verification rhuMAb Beta7; RG7413; PRO145223	Integrin	Cancer
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with K_i values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .

HY-N0840

Bruceantin 2 Publications Verification (-)-Bruceantin; NCI165563; NSC165563	c-Myc Caspase Mitochondrial Metabolism Apoptosis Parasite	Infection Cancer
Bruceantin ((-)-Bruceantin) is a quassinoid found in B. javanica. Bruceantin activates caspase signaling pathway, causes the mitochondrial dysfunction, inhibits cell proliferation, induces cell differentiation and apoptosis. Bruceantin exhibits anti-leukemia and antiprotozoal activities .

HY-161574

LLC0424	PROTACs Histone Methyltransferase	Cancer
LLC0424 is a potent and selective cereblon-based PROTAC nuclear receptor-binding SET domain-containing 2 (NSD2) degrader. LLC0424 effectively degraded NSD2 with a DC₅₀ of 20 nM in RPMI-8402 cells. LLC0424 selectively induces NSD2 degradation in a cereblon- and proteasome-dependent fashion. (Blue: CRBN ligand (HY-14658), Black: linker (HY-40002); Pink: NSD2 inhibitor (HY-161575)) .

HY-164099

LSD1/HDAC6-IN-2	HDAC Monoamine Oxidase Histone Demethylase	Cancer
LSD1/HDAC6-IN-2 (JBI-802) is an orally active LSD1/HDAC6/MAO-A inhibitor, with IC₅₀ values of 5 nM, 11 nM, and 5 nM, respectively. LSD1/HDAC6-IN-2 can inhibit the growth of multiple myeloma cells MM.1S, MM.1R, and RPMI-8226. LSD1/HDAC6-IN-2 can be used for research on diseases such as acute myeloid leukemia and lymphoma .

HY-145564

Emprumapimod PF-07265803	p38 MAPK	Cardiovascular Disease Inflammation/Immunology
Emprumapimod (PF-07265803) is a potent, orally active and selective inhibitor of p38α MAPK directly inhibits LPS-induced IL-6 production from RPMI-8226 cell (IC₅₀=100 pM). Emprumapimod can be used for the research of dilated cardiomyopathy and acute inflammatory pain .

HY-10455R

Carfilzomib (Standard) PR-171 (Standard)	Reference Standards Proteasome Autophagy Apoptosis	Cancer
Carfilzomib (Standard) is the analytical standard of Carfilzomib. This product is intended for research and analytical applications. Carfilzomib (PR-171) is an irreversible proteasome inhibitor with an IC₅₀ of 5 nM in ANBL-6 and RPMI 8226 cells.

HY-U00460

3,6-DMAD hydrochloride 1 Publications Verification	IRE1	Cancer
3,6-DMAD hydrochloride, an acridine derivative, is a potent IRE1α-XBP1s pathway inhibitor. 3,6-DMAD hydrochloride promotes IL-6 secretion via the IRE1α-XBP1s pathway. 3,6-DMAD hydrochloride inhibits IRE1α oligomerization and endoribonuclease (RNase) activity. 3,6-DMAD hydrochloride can be used for research of cancer .

HY-155231

Neutrophil elastase inhibitor 4	Elastase	Cancer
Neutrophil elastase inhibitor 4 (compound 4f) is a competitive human neutrophil elastase (HNE) inhibitor (IC₅₀: 42.30 nM, K_i: 8.04 nM). Neutrophil elastase inhibitor 4 induces T47D cell apoptosis. Neutrophil elastase inhibitor 4 inhibits cell proliferation with IC₅₀s of 21.25, 34.17, 29.93, 99.11 nM for T47D, RPMI 8226, A549, and HSF cells .

HY-10455S

Carfilzomib-d8	Isotope-Labeled Compounds Proteasome Autophagy Apoptosis	Cancer
Carfilzomib-d₈ is deuterium labeled Carfilzomib. Carfilzomib (PR-171) is an irreversible proteasome inhibitor with an IC50 of 5 nM in ANBL-6 and RPMI 8226 cells.

HY-174984

VCP/p97 IN-3	p97 Caspase p62	Cancer
VCP/p97 IN-3 is a VCP/p97 allosteric inhibitor. VCP/p97 IN-3 shows the inhibitory activity against the VCP proteins with an IC₅₀ of 9 nM and the mutant VCP proteins with IC₅₀ of 12 nM (N660K) and 19 nM (V474A/D649A). VCP/p97 IN-3 increases K48-linked ubiquitination and the level of cleaved caspase-3. VCP/p97 IN-3 activates ER-stress and the UPR. VCP/p97 IN-3 inhibits tumor growth in RPMI-8226 cell subcutaneous xenograft mouse models. VCP/p97 IN-3 can be used for the study of multiple myeloma .

HY-177740

BTX306	Molecular Glues Apoptosis Caspase	Cancer
BTX306 is a cereblon-targeting molecular glue degrader. BTX306 reduces myeloma cell viability and induces apoptosis. BTX306 overcomes myeloma cell resistance to Lenalidomide (HY-A0003) or Bortezomib (HY-10227). BTX306 is active against primary myeloma cells, and shows efficacy in vivo. BTX306 can be used for myeloma research .

HY-177768

HDAC-IN-96	HDAC Apoptosis	Cancer
HDAC-IN-96 (Compound 3f) is a selective HDAC1/2 inhibitor with IC₅₀ values of 457.1 and 433.7 nM. HDAC-IN-96 has strong inhibitory activity against multiple hematological tumor cells (RS4;11, K562, RPMI-8226, U266), with IC₅₀ values ranging from 2.11 to 5.35 μM. HDAC-IN-96 can induce cancer cells apoptosis and S phase arrest. HDAC-IN-96 can be used for the research of cancer, such as acute lymphoblastic leukemia .

HY-U00460B

3,6-DMAD dihydrochloride	IRE1	Cancer
3,6-DMAD dihydrochloride, an acridine derivative, is a potent IRE1α-XBP1s pathway inhibitor. 3,6-DMAD dihydrochloride promotes IL-6 secretion via the IRE1α-XBP1s pathway. 3,6-DMAD dihydrochloride inhibits IRE1α oligomerization and endoribonuclease (RNase) activity. 3,6-DMAD dihydrochloride can be used for research of cancer .

HY-15473A

MLN120B dihydrochloride 25+ Cited Publications ML120B dihydrochloride	IKK	Inflammation/Immunology Cancer
MLN120B dihydrochloride (ML120B dihydrochloride) is a potent, ATP competitive, and orally active inhibitor of IKKβ with an IC₅₀ of 60 nM. MLN120B inhibits multiple myeloma cell growth in vitro and in vivo and also can be used for the research of rheumatoid arthritis .

HY-144369

Proteasome-IN-4	Proteasome	Cancer
Proteasome-IN-4 is an excellent and non-covalent proteasome inhibitor (IC₅₀=8.39 nM). Proteasome-IN-4 has potent antiproliferative activities against RPMI-8226, MM-1S and MV-4-11 cell lines. Proteasome-IN-4 can be used for cancer research .

HY-168338

CB2 receptor agonist 8	Cannabinoid Receptor Caspase	Cancer
CB2 receptor agonist 8 (Compound 17) is an agonist for cannabinoid receptor 2 (CB2 receptor). CB2 receptor agonist 8 exhibits cytotoxicity in cells U87, RPMI 8226, HL-60, and L929 with IC₅₀s of 91.03, 16.29, 23.51 and 564.6 μM, respectively. CB2 receptor agonist 8 activates caspase 3/7, increases the expressions of pro-apoptotic genes BAX, BAD, BIM and tumor suppressor genes p53, and induces apoptosis in U87. CB2 receptor agonist 8 inhibits the migration of U87 .

HY-125152

Candicidin D CndD	Antibiotic Fungal	Infection
Candicidin D (CndD) is an antibiotic, which exhibits antifungal activity through interaction with steroids in cell membranes. Candicidin D inhibits S. cerevisiae, Candida albicans and other Candida spp. with MIC of 0.25-1 μg/mL in RPMI-1640 medium.

HY-149832

Anticancer agent 114	Proteasome	Cancer
Anticancer agent 114 is a potent and orally active dipeptide boronic acid ester proteasome inhibitor with an IC₅₀ value of 2.2 nM. Anticancer agent 114 has antiproliferative activity against the RPMI-8226 cells. Anticancer agent 114 can be used in research of multiple myeloma .

HY-P991462

GBR-1342	CD38	Cancer
GBR-1342 is a human bispecific antibody (bsAb) targeting CD38 & CD3. GBR-1342 inhibits the activity of Daudi, RAJI, RPMI8226, IM-9, and NCI-H929 cancer cell lines. GBR-1342 can be used in myeloma research .

HY-155671

HDAC6-IN-18	HDAC	Cancer
HDAC6-IN-18 (Compound 4) is a first irreversible HDAC6 isoform selective inhibitor with potent anti-multiple myeloma activity. HDAC6-IN-18 has HDAC6 inhibitory activity in RPMI8266, U266 and MM.1S cells with IC₅₀ values of 0.17, 0.7 and 0.42 μM, respectively .

HY-180469

N-Desmethyl clindamycin hydrochloride	Drug Metabolite DNA/RNA Synthesis	Infection Cancer
N-Desmethyl clindamycin hydrochloride is the main metabolite of Clindamycin (HY-B1455). N-Desmethyl clindamycin hydrochloride shows potent cytotoxicity against L1210, KB,RPMI 6410 and RPMI 1788 cancer cells with LD₅₀ values of 0.07, 0.29, 0.13 and 0.32 μM. N-Desmethyl clindamycin hydrochloride can inhibit cell DNA, RNA and protein synthesis. N-Desmethyl clindamycin hydrochloride can be used for the research of infection and cancer .

HY-104040R

MKC8866 (Standard) Orin1001 (Standard)	Reference Standards IRE1	Cancer
MKC8866 (Standard) is the analytical standard of MKC8866 (HY-104040). This product is intended for research and analytical applications. MKC8866, a salicylaldehyde analog, is a potent, selective IRE1 RNase inhibitor with an IC₅₀ of 0.29 μM in human vitro. MKC8866 strongly inhibits Dithiothreitol-induced X-box-binding protein 1-spliced (XBP1s) expression with an EC₅₀ of 0.52 μM and unstresses RPMI 8226 cells with an IC₅₀ of 0.14 μM . MKC8866 inhibits IRE1 RNase in breast cancer cells leading to the decreased production of pro-tumorigenic factors and it can inhibits prostate cancer (PCa) tumor growth .

HY-181234

Y502-3888	c-Myc Apoptosis	Cancer
Y502-3888 is a c-Myc inhibitor. Y502-3888 binds to the c-Myc G4 structure, inhibits c-Myc transcription, and downregulates c-Myc expression at both mRNA and protein levels. Y502-3888 inhibits the viability of myeloma cells and induces cell apoptosis. Y502-3888 can be used for the research of multiple myeloma .

Cat. No.	Product Name	Type

HY-150287

Insulin-Transferrin-Selenium, 100X 5+ Cited Publications ITS-G	Biochemical Assay Reagents
Insulin-Transferrin-Selenium, 100X (ITS-G) is a mixture of Insulin, transferrin, and sodium selenite that is a general supplement designed for use in classic media such as DMEM, RPMI-1640, and nutrient media such as Ham's F-12, DMEM/F-12. Insulin-Transferrin-Selenium is added to basal medium to reduce the amount of fetal calf serum required to culture cells .

Cat. No.	Product Name

HY-K3025

D-Glucose Solution (200 g/L)
MCE D-Glucose Solution (200 g/L) can be used as a serum-free supplement for cell culture media and is suitable for a variety of culture systems, including but not limited to DMEM, RPMI 1640, DMEM/F-12, IMDM, and MEM.

HY-K3004

RPMI 1640 (L-Glutamine, Phenol Red, no HEPES) 4 Publications Verification
RPMI 1640 contains glutathione and high concentration of vitamins, also contains biotin, vitamin B12, 4-Aminobenzoic acid (PABA) not found in MEM and DMEM, as well as high concentration of inositol and choline chloride. The 500 mL is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

Cat. No.	Product Name	Target	Research Area	Image